Clinical trials: Antipsychotic
Psychotic Disorders
Family Perspectives:Treatment of Psychiatric Illnesses With Atypical Long Acting Injectable Antipsychotic Medication
Patients who have schizophrenia, schizoaffective disorder, a psychotic disorder, and are being treated with a medication called Risperidone Long Acting Injectable medication or another antipsychotic medication are candidates for…
- Trial name
- NCT00287027
- Testing
- Risperdal Long Acting Injectable Antipsychotic Medication
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Alliance on Mental Illness New Hampshire
Huntington Disease
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Huntington's disease (HD) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade.
- Trial name
- NEUROHD (NCT00632645)
- Testing
- Olanzapine, Xenazine, Tiapridal
- Where
- France
- Volunteers
- 180 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Schizophrenia
A Pilot Study of the Use of Risperidone Long Acting Injectable in the Treatment of Patients With Recent Onset Psychosis
The purpose of the study is to assess the effectiveness and safety of long-acting injectable risperidone in the treatment of patients in the early stage of psychosis
- Trial name
- NCT00216580
- Testing
- Risperidone, long-acting injectable
- Volunteers
- 50 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Clinical High-risk
A Study of Antipsychotics in Individuals at Clinical High-risk for Psychosis (the SHARP-2 Study)
The current study will improve knowledge on the effectiveness and safety of the use of antipsychotics at the prodromal phase and on factors influencing the outcome, and will eventually facilitate optimisation of individualised…
- Trial name
- NCT04010864
- Testing
- routine clinical treatment
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia, Schizophrenic Disorders
Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.
The purpose of this open-label study is to evaluate the long-term (6-month) safety and tolerability of extended-release paliperidone, an atypical antipsychotic, given in flexible dosages to adolescents with schizophrenia.
- Conditions
- Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
- Trial name
- NCT00488319
- Testing
- Paliperidone ER
- Where
- 53 sites in United States, Belgium and 9 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Psychosis
Immune Mechanisms of Antipsychotic Treatment Response
The aim of this study is to investigate the role of the immune system in psychotic symptoms and their response to treatment. The investigators will collect blood and cerebrospinal fluid samples from participants with psychosis…
- Trial name
- IMAT (NCT06687694)
- Where
- United Kingdom
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- King's College London
Dyskinesia, Drug-Induced
Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
The aim of the present study was to investigate the efficacy of aripiprazole in management of pre-existing neuroleptic-induced tardive dyskinesia
- Trial name
- NCT00837707
- Testing
- aripiprazole
- Where
- Taiwan
- Volunteers
- 25 people
- Sponsor
- Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan
Adverse Effect of Other Antipsychotics and Neuroleptics
Adverse Events and Genomics in Schizophrenia
The purpose of this study is to find genes that predict whether or not a person will develop side effects to antipsychotic medications, such as weight gain, blood sugar dysregulation, or immune cell abnormalities.
- Trial name
- AEGIS (NCT01966588)
- Testing
- Blood samples for whole genomic/transcriptomic sequencing, UKU Side Effect Rating Scale
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Schizophrenia
An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia
The purpose of this study is to determine whether aripiprazole injection into the shoulder or the buttocks produces similar effects in the body
- Trial name
- NCT01646827
- Testing
- Aripiprazole IM Depot
- Where
- 6 sites in United States
- Volunteers
- 37 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Trial to Assess the Antipsychotic Efficacy of ITI-007
The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.
- Trial name
- NCT02282761
- Testing
- ITI-007
- Where
- 11 sites in United States
- Volunteers
- 450 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Schizophrenia
Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects
This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications.
- Trial name
- NCT00815854
- Testing
- Folic Acid
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- University of Michigan
Schizophrenia
Energy Homeostasis Under Treatment With Atypical Antipsychotics
The purpose of this study is to evaluate the effects of different atypical antipsychotics on weight changes, energy homeostasis, metabolism, energy intake as well as activity.
- Trial name
- NCT00148564
- Testing
- olanzapine, Ziprasidone
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Charite University, Berlin, Germany
Schizophrenia, Obesity
Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia
Background: Although second-generation antipsychotic medications have fewer serious side effects and complications than first-generation ones, they are strongly associated with weight gain for reasons that are as yet unknown.
- Trial name
- NCT01222793
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute on Drug Abuse (NIDA)
Alcohol Relapse Prevention, Alcoholism
Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study
Due to Quetiapine's particulars and the promising receptor profile, we want to examine the efficacy concerning relapse prevention of alcoholics suffering from persisting craving and/or affective symptoms (persisting sleep…
- Conditions
- Alcohol Relapse Prevention, Alcoholism, Alcohol Drinking, Alcohol Consumption
- Trial name
- NCT00561587
- Testing
- Seroquel®
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH
Adverse Effects
A Prospective Study to Assess Metabolic Changes in Children and Adolescents Treated With Atypical Antipsychotics
The purpose of this study is to observe patients aged 6-18 with various psychiatric diagnosis being treated with drugs called atypical antipsychotics to determine the effects of the drugs on growth, weight gain, and laboratory…
- Trial name
- NCT00480168
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Impaired Cognition
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
This study is being conducted to further investigate the safety of prolonged exposure to EVP-6124 in subjects with Schizophrenia receiving a stable dose of an atypical antipsychotic who completed double-blind treatment on studies…
- Trial name
- NCT01714713
- Testing
- EVP-6124
- Where
- 128 sites in United States, Argentina and 14 more
- Volunteers
- 830 people
- Sponsor
- FORUM Pharmaceuticals Inc
Major Depressive Disorder and Irritability
Brexpiprazole (OPC 34712) Trial in the Treatment of Adults With Major Depressive Disorder and Irritability
The purpose of this study is to explore the effects of fixed-dosed brexpiprazole adjunctive treatment in subjects with Major Depressive Disorder with irritability
- Trial name
- NCT02212613
- Testing
- Brexpiprazole
- Where
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Insulin Resistance, Menstrual Cycle
Effects of Antipsychotics on Brain Insulin Action in Females
Females treated with antipsychotics have higher rates of comorbid metabolic syndrome than males. Despite this, females have historically been excluded from many mechanistic studies due to confounding effects of menstrual cycles.
- Conditions
- Insulin Resistance, Menstrual Cycle, Type 2 Diabetes, Antipsychotics
- Trial name
- NCT06251635
- Testing
- Olanzapine 2.5Mg Oral Tablet, Insulin Lispro 100 UNT/ML, Saline
- Where
- Canada
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Schizophrenia, Schizoaffective Disorder
Glucose and Lipid Metabolism on Antipsychotic Medication
This project aims to a) evaluate the effects of selected antipsychotic medications on insulin action in skeletal muscle (glucose disposal), liver (glucose production) and adipose tissue (whole-body lipolysis), b) evaluate the…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
- Trial name
- Glulipid (NCT00515723)
- Testing
- risperidone, olanzapine, quetiapine
- Where
- 2 sites in United States
- Volunteers
- 96 people
- Sponsor
- Washington University School of Medicine